| # | Title | Journal | Year | Citations |
|---|
| 1 | Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years | Hum Vaccin | 2009 | 336 |
| 2 | Development of a survey to identify vaccine-hesitant parents | Hum Vaccin | 2011 | 285 |
| 3 | Development of a metabolically active, non-replicating sporozoite vaccine to preventPlasmodium falciparummalaria | Hum Vaccin | 2010 | 258 |
| 4 | From the circumsporozoite protein to the RTS,S/AS candidate vaccine | Hum Vaccin | 2010 | 217 |
| 5 | Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond | Hum Vaccin | 2011 | 214 |
| 6 | Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection | Hum Vaccin | 2009 | 184 |
| 7 | Prime-boost vectored malaria vaccines: Progress and prospects | Hum Vaccin | 2010 | 184 |
| 8 | Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All | Hum Vaccin | 2006 | 183 |
| 9 | Performance of rotavirus vaccines in developed and developing countries | Hum Vaccin | 2010 | 174 |
| 10 | Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials | Hum Vaccin | 2009 | 171 |
| 11 | Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule | Hum Vaccin | 2011 | 163 |
| 12 | Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine | Hum Vaccin | 2008 | 157 |
| 13 | Human pathogenic hantaviruses and prevention of infection | Hum Vaccin | 2011 | 144 |
| 14 | Virus‑like particles as a vaccine delivery system: Myths and facts | Hum Vaccin | 2008 | 141 |
| 15 | Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine | Hum Vaccin | 2011 | 141 |
| 16 | BCG Vaccines: Their mechanisms of attenuation and impact on safety and protective efficacy | Hum Vaccin | 2009 | 131 |
| 17 | Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants | Hum Vaccin | 2011 | 131 |
| 18 | Transcutaneous and intradermal vaccination | Hum Vaccin | 2011 | 129 |
| 19 | Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions | Hum Vaccin | 2007 | 120 |
| 20 | Preclinical and Clinical Safety Studies on DNA Vaccines | Hum Vaccin | 2006 | 111 |
| 21 | Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens inCervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine | Hum Vaccin | 2010 | 111 |
| 22 | Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults | Hum Vaccin | 2009 | 110 |
| 23 | Recent developments for Pseudomonas vaccines | Hum Vaccin | 2011 | 108 |
| 24 | Trust and Experience as Predictors of HPV Vaccine Acceptance | Hum Vaccin | 2007 | 107 |
| 25 | Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers | Hum Vaccin | 2009 | 100 |
| 26 | Genetically engineered, attenuated whole-cell vaccine approaches for malaria | Hum Vaccin | 2010 | 100 |
| 27 | Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years | Hum Vaccin | 2011 | 100 |
| 28 | Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccines against Japanese Encephalitis (ChimeriVaxTM-JE) in Non-Human Primates | Hum Vaccin | 2005 | 99 |
| 29 | The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay | Hum Vaccin | 2011 | 97 |
| 30 | The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans | Hum Vaccin | 2009 | 94 |
| 31 | Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines | Hum Vaccin | 2011 | 94 |
| 32 | rDEN2/4Δ30(ME), a Live Attenuated Chimeric Dengue Serotype 2 Vaccine, is Safe and Highly Immunogenic in Healthy Dengue-Naïve Adults | Hum Vaccin | 2006 | 93 |
| 33 | Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza | Hum Vaccin | 2011 | 93 |
| 34 | Development of sanofi pasteur tetravalent dengue vaccine | Hum Vaccin | 2010 | 92 |
| 35 | The Live Attenuated Dengue Serotype 1 Vaccine rDEN1Δ30 is Safe and Highly Immunogenic in Healthy Adult Volunteers | Hum Vaccin | 2006 | 89 |
| 36 | Current status ofPlasmodium vivaxvaccine | Hum Vaccin | 2010 | 86 |
| 37 | Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly | Hum Vaccin | 2005 | 84 |
| 38 | The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia | Hum Vaccin | 2008 | 81 |
| 39 | Lactococcus lactisas a live vector for mucosal delivery of therapeutic proteins | Hum Vaccin | 2009 | 81 |
| 40 | Argentine hemorrhagic fever vaccines | Hum Vaccin | 2011 | 81 |
| 41 | Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge | Hum Vaccin | 2007 | 79 |
| 42 | Scrub Typhus Vaccines: Past History and Recent Developments | Hum Vaccin | 2007 | 79 |
| 43 | Protective immunity following vaccination: How is it defined? | Hum Vaccin | 2008 | 77 |
| 44 | Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents | Hum Vaccin | 2010 | 77 |
| 45 | Molecular and cellular mechanisms of DNA vaccines | Hum Vaccin | 2008 | 76 |
| 46 | A comparison of anionic nanoparticles and microparticles as vaccine delivery systems | Hum Vaccin | 2008 | 76 |
| 47 | Advances and challenges towards a vaccine against Chagas disease | Hum Vaccin | 2011 | 76 |
| 48 | Recombinant vaccines against Leptospirosis | Hum Vaccin | 2011 | 75 |
| 49 | Correlation between Mouse Potency and In Vitro Relative Potency for Human Papillomavirus Type 16 Virus-Like Particles and Gardasil® Vaccine Samples | Hum Vaccin | 2005 | 74 |
| 50 | Sex differences in injection site reactions with human vaccines | Hum Vaccin | 2009 | 74 |
